Idatha Entsha Ngezimila Zengqondo Yezingane

I-Kazia Therapeutics Limited imemezele idatha entsha ye-preclinical ebonisa umsebenzi we-paxalisib ezinhlotsheni ezimbili zomdlavuza wobuchopho bezingane ezinesidingo sezokwelapha esiphezulu kakhulu esingahlangabeziwe.       

Le datha iyisihloko sezifinyezo ezintathu ezethulwe eMhlanganweni Wonyaka we-American Association for Cancer Research (AACR), owawuseNew Orleans, LA, kusukela ngo-Ephreli 8 - 13, 2022.

Izifushaniso ezimbili zososayensi abasebenza elabhorethri yoMsizi uSolwazi uJeffrey Rubens e-Johns Hopkins University e-Baltimore, MD, zichaza ukusetshenziswa kwe-paxalisib njengendlela yokwelapha umgogodla kumdlavuza wobuchopho bezingane owaziwa ngokuthi yi-atypical teratoid / rhabdoid tumors (AT/RT). Kungokokuqala ngqa ukuthi kwethulwe idatha ehlola i-paxalisib ngalolu hlobo lomdlavuza wobuchopho, futhi ivula inkomba entsha ebalulekile engase ibe khona emthini.

I-abstract yesithathu, evela eqenjini elihlukile lososayensi base-Johns Hopkins University, eholwa nguSolwazi u-Eric Raabe kanye noDkt Katherine Barnett, ikhombise ubufakazi bokusebenzisana okuqinile phakathi kwe-paxalisib nelinye ikilasi lokwelapha umdlavuza kumodeli ye-diffuse intrinsic pontine glioma (DIPG) . I-Paxalisib ibonise ngaphambilini ubufakazi bokusebenza kulesi sifo, kokubili njenge-monotherapy futhi ihlangene nezinhlobo eziningana zokwelapha umdlavuza, futhi idatha entsha iqinisekisa amandla ayo kulesi sifo esiyinselele kakhulu.

Amaphuzu ayisihluthulelo

• I-AT/RT iwumdlavuza wobuchopho ongavamile ohlasela kakhulu izinsana nezingane ezincane. Azikho izidakamizwa ezigunyazwe yi-FDA ze-AT/RT futhi izinketho ezikhona zokwelapha zilinganiselwe kakhulu. Isiguli esingaphansi kwesinye kweziyisihlanu siphila eminyakeni engaphezu kwemibili kusukela ekuxilongweni.

• Idatha evela kulabhorethri kaSolwazi Rubens ibonisa ukuthi indlela ye-PI3K ivamise ukwenziwa kusebenze ku-AT/RT, nokuthi ukwelashwa nge-paxalisib iyodwa kusebenza kumamodeli angaphambi komtholampilo wesifo. Ngaphezu kwalokho, ukuhlanganiswa ne-RG2822, i-HDAC inhibitor, noma i-TAK580, i-MAPK inhibitor, kubonakala kunweba kakhulu ukuphila uma kuqhathaniswa nokwelashwa kwe-monotherapy.

• I-DIPG iwumdlavuza wobuchopho ongandile ovame ukubonakala ezinganeni ezincane kanye nentsha. Azikho izidakamizwa ezigunyazwe yi-FDA, futhi isilinganiso seminyaka yokuphila kusukela ekuxilongweni ngokuvamile silinganiselwa ezinyangeni eziyishumi.

• Idatha yangaphambilini evela emaqenjini amaningana abacwaningi, futhi ikakhulukazi ethimbeni likaSolwazi Matt Dun e-Hunter Medical Research Institute, ibonise ukuthi i-paxalisib isebenza kakhulu ku-DIPG futhi ihlangana ngokubambisana nemithi yomdlavuza eminingana.

• Idatha evela kuDkt Raabe no-Barnett kanye nozakwabo ikhomba inhlanganisela yokwelapha yenoveli eyengeziwe, ne-HDAC inhibitor RG2833, ebonisa ubufakazi bokusebenzisana okuqinile kumodeli yangaphambi kwekliniki ye-DIPG.

Isikhulu seKazia, uDkt James Garner, wengeze ngokuthi, “Lokhu kuyidatha ethembisayo kakhulu, futhi sibonga ithimba lase-Johns Hopkins ngalolu cwaningo olubalulekile nolukhuthazayo. I-Paxalisib isivele iyisihloko sohlolo oluqhubekayo lwesigaba sesi-II somtholampilo ku-DIPG kanye nokusabalalisa ama-gliomas aphakathi nendawo (NCT05009992) futhi le datha entsha iphakamisa ukusetshenziswa okubanzi okungaba khona komuthi kumdlavuza wobuchopho bezingane. Sibheke ngabomvu ukusebenzisana nethimba lika-Johns Hopkins, kanye nabanye ozakwethu nabeluleki, ukuhlola la mathuba ngokuqhubekayo.”